1,4-Dihydroxy-2-naphthoic acid

1,4-Dihydroxy-2-naphthoic acid 是一种芳烃受体 (AhR) 激动剂,也是一种具有抗炎活性的细菌衍生代谢物。
产品编号: MS-Z78777 纯度: 99.60% CAS No.: 31519-22-9 分子式: C11H8O4 分子量: 204.18
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1g
询价
3-5 天
5g
询价
询价
10g
询价
询价

产品描述

1,4-Dihydroxy-2-naphthoic acid 是一种芳烃受体 (AhR) 激动剂,也是一种具有抗炎活性的细菌衍生代谢物。

生物实验数据

生物活性 1,4-Dihydroxy-2-naphthoic acid is an aryl hydrocarbon receptor (AhR) agonist and a bacteria-derived metabolite with anti-inflammatory activity.
体外研究
(In Vitro)

1,4-Dihydroxy-2-naphthoic acid (25-1000 μM, 18-24 h) 在 YAMC 和 Caco2 细胞中诱导 CYP1A1 和 CYP1B1 表达超过 70%。
1,4-Dihydroxy-2-naphthoic acid (100 μM, 24 h) 抑制 LPS (MS-X54539) 刺激的 RAW264.7 细胞中 IL-1β、IL-6、IL-23、p19 和 IL-17A mRNA 水平。
1,4-Dihydroxy-2-naphthoic acid (48-72 h) 抑制 HaCaT、NCTC 2544、Hs-69 和 PIG1 细胞增殖,72 小时 IC50 分别为 38.94、46.80、226.3 和 23.98 μM。
1,4-Dihydroxy-2-naphthoic acid (15-120 μM, 9-72 h) 在 HaCaT 细胞中时间和剂量依赖性诱导凋亡和 G0/G1 期阻滞。
1,4-Dihydroxy-2-naphthoic acid (30-240 μM, 24-48 h) 可降低 HaCaT 细胞线粒体膜电位,增加 DNA 断裂,并导致 AIF 和 endoG 核转位。
1,4-Dihydroxy-2-naphthoic acid (20-100 μM, 72 h) 对皮肤刺激性较低,仅在 60 μM 浓度下显著诱导 NCTC2544 细胞释放 IL-1α。

RT-PCR

Cell Line: YAMC and Caco2 cells
Concentration: 25, 50, 100, 250, 500, 1000 μM
Incubation Time: 18 h
Result: Induced Cyp1a1 and Cyp1b1 in both cells.
Completely eliminated the induction effects on Cyp1a1 and Cyp1b1 when the AhR was knocked out.

Western Blot Analysis

Cell Line: YAMC and Caco2 cells
Concentration: 500 μM
Incubation Time: 24 h
Result: Induced Cyp1a1 and Cyp1b1 expression in both cells.

RT-PCR

Cell Line: LPS-stimulated RAW264.7 cells
Concentration: 100 μM
Incubation Time: 24 h
Result: Inhibited IL-1β, IL-6, IL-23p19 and IL-17A mRNA levels in RAW264.7 cells.

Apoptosis Analysis

Cell Line: HaCaT cells
Concentration: 30, 60 and 120 μM
Incubation Time: 9, 24 and 72 h
Result: Increased in nuclear fluorescence from dark blue to light blue/white (chromatin condensation) at 30 and 60 μM.
Formed apoptotic bodies at 120 μM.
Increased apoptosis ratio time dependently.
Activated Caspase-8 and Caspase-9 and cleavage PARP and Bid.

Apoptosis Analysis

Cell Line: HaCaT cells
Concentration: 15, 30, 60 and 120 μM
Incubation Time: 24 h
Result: Dose-dependently induced G0/G1 cell cycle arrest.
Upregulated p21, while downregulated Cyclin D1/D3 and Cdk4.
体内研究
(In Vivo)

1,4-Dihydroxy-2-naphthoic acid (20 mg/kg, p.o., 共 5-10 周) 成功预防和逆转不可预测性慢性轻度应激(UCMS) 小鼠的快感缺乏样行为。
1,4-Dihydroxy-2-naphthoic acid (2 mg/kg, p.o., 共 14 天) 通过抑制巨噬细胞来源的促炎细胞因子减轻了小鼠结肠炎。
1,4-Dihydroxy-2-naphthoic acid (20 mg/kg, p.o., 共 3 周) 预防了由 MPTP (MS-O89430) 诱导的小鼠运动功能障碍。

Animal Model: UCMS model established in female C57BL/6 mice (6-7 weeks)
Dosage: 20 mg/kg
Administration: Oral administration (p.o.), once daily, 3 weeks prior to UCMS or 2 weeks after UCMS, for 5-10 weeks
Result: Did not exhibit a reduction in sucrose preference.
Restored the activity of Ca-ATPase and glycogen levels, and reduced phospholipase and lipid peroxides.
Did not significantly affect open field test (OFT), marble bury (MB) and novelty-induced hypophagia (NIH) behaviors.
Had no significant effect on the light/dark (L/D) test or on anxiety behaviors in the elevated plus maze (EPM).
Had a significant effect on spatial learning in unstressed animals.
Animal Model: Colitis model established in 8-week male interleukin-10-deficient mice
Dosage: 2 mg/kg
Administration: Oral administration (p.o.) with water freely available, for 14 days
Result: Significantly reduced the inflammation score.
Significantly reduced F4/80⁺ cells and VCAM-1 expression.
Significantly inhibited IL-1β, IL-6, TNF-α, IL-23p19 and IL-17A mRNA levels.
Animal Model: Parkinson's disease (PD) model established in male C57BL/6 mice
Dosage: 20 mg/kg
Administration: Oral administration (p.o.), for 3 weeks
Result: Prevented MPTP-induced deficits in the motor pole test and in the adhesive strip removal test.
Improved balance beam performance and completely prevented MPTP-induced reduction in stride length.
性状 固体
颜色 Gray to brown

化学信息

分子量 204.18
分子式 C11H8O4
CAS No. 31519-22-9

储存&溶解度

储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 175 mg/mL (857.09 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM4.8976 mL24.4882 mL48.9764 mL122.4410 mL
5 mM0.9795 mL4.8976 mL9.7953 mL24.4882 mL
10 mM0.4898 mL2.4488 mL4.8976 mL12.2441 mL
15 mM0.3265 mL1.6325 mL3.2651 mL8.1627 mL
20 mM0.2449 mL1.2244 mL2.4488 mL6.1220 mL
25 mM0.1959 mL0.9795 mL1.9591 mL4.8976 mL
30 mM0.1633 mL0.8163 mL1.6325 mL4.0814 mL
40 mM0.1224 mL0.6122 mL1.2244 mL3.0610 mL
50 mM0.0980 mL0.4898 mL0.9795 mL2.4488 mL
60 mM0.0816 mL0.4081 mL0.8163 mL2.0407 mL
80 mM0.0612 mL0.3061 mL0.6122 mL1.5305 mL
100 mM0.0490 mL0.2449 mL0.4898 mL1.2244 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础